Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Head and Neck Cancers - Salivary Gland 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1

Interventions

pembrolizumab 35Cetuximab 18Gemcitabine 14Nivolumab 13Cisplatin 13Paclitaxel 10Carboplatin 9Cyclophosphamide 7cemiplimab 6Fluorouracil 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 5fludarabine 4durvalumab 4aldesleukin 4Immune Checkpoint Inhibitors 4Biopsy 4fludarabine phosphate 3Valproic Acid 3Radiation 3Interleukin-2 3Drug Therapy 3Bevacizumab 3130-nm albumin-bound paclitaxel 3tislelizumab 2sintilimab 2avelumab 2apatinib 2Tablets 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × surufatinib × Head & Neck × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡